Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down – Here’s What Happened

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) shares gapped down prior to trading on Monday . The stock had previously closed at $96.53, but opened at $89.50. Mirum Pharmaceuticals shares last traded at $106.1650, with a volume of 221,222 shares trading hands.

Trending Headlines about Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Topline clinical win: Mirum said the VISTAS study met its primary endpoint for volixibat in primary sclerosing cholangitis — a major development that expands the drug’s market potential and underpins optimism about peak sales and strategic options. Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study
• Positive Sentiment: Raised fiscal?year revenue outlook: Management guided FY2026 revenue to $660–$680 million, above consensus (~$644M), signaling stronger commercial traction and helping investor sentiment. Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results
• Positive Sentiment: Revenue beat and solid top?line growth: Q1 revenue was $159.9M (up ~43% YoY) and topped analyst estimates, showing underlying commercial momentum even as EPS was negative on a GAAP basis. Mirum Reports Q1 Loss, Beats Revenue Estimates
• Neutral Sentiment: Corporate filings and conference call available: Management released the Q1 report and held an earnings call; the press release and transcript give detail on guidance, one?time items and commercial trends for investors to parse. View Press Release / Conference Materials
• Negative Sentiment: Large GAAP EPS miss: Reported EPS of ($13.43) materially missed consensus (around ($0.40)); the disparity appears tied to non?operational items disclosed in filings, which created headline risk despite the revenue beat. Earnings Report and Conference Call
• Negative Sentiment: Analyst estimate cuts: HC Wainwright trimmed quarterly and FY2026 EPS forecasts even while maintaining a Buy rating and a $175 target, reflecting model revisions that add near?term earnings uncertainty. HC Wainwright Lowers EPS Estimates

Wall Street Analysts Forecast Growth

MIRM has been the topic of several recent research reports. Leerink Partners reduced their price target on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating on the stock in a research report on Thursday, February 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Tuesday, April 21st. TD Cowen lifted their target price on Mirum Pharmaceuticals from $117.00 to $125.00 and gave the company a “buy” rating in a research report on Friday, March 27th. Robert W. Baird lifted their price target on Mirum Pharmaceuticals from $95.00 to $112.00 and gave the stock an “outperform” rating in a report on Tuesday, April 28th. Finally, Stifel Nicolaus lifted their price target on Mirum Pharmaceuticals from $125.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $125.25.

Mirum Pharmaceuticals Stock Up 4.0%

The firm’s fifty day moving average price is $93.88 and its 200-day moving average price is $85.86. The company has a market capitalization of $6.71 billion, a price-to-earnings ratio of -229.33 and a beta of 0.52. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.67 and a quick ratio of 2.55.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($13.03). The company had revenue of $159.88 million during the quarter, compared to analyst estimates of $148.21 million. Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The business’s revenue for the quarter was up 43.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.30) earnings per share. Sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -1.81 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Peter Radovich sold 16,515 shares of the firm’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $1,519,049.70. Following the transaction, the chief operating officer owned 40,272 shares of the company’s stock, valued at approximately $3,704,218.56. This trade represents a 29.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jolanda Howe sold 4,732 shares of the firm’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $435,249.36. Following the completion of the transaction, the senior vice president directly owned 8,429 shares in the company, valued at approximately $775,299.42. The trade was a 35.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 76,806 shares of company stock worth $7,064,616 over the last 90 days. 14.36% of the stock is owned by company insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC lifted its position in shares of Mirum Pharmaceuticals by 21.4% during the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock worth $479,050,000 after buying an additional 1,067,722 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Mirum Pharmaceuticals by 2.0% in the 4th quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company’s stock worth $205,065,000 after purchasing an additional 50,720 shares during the period. State Street Corp raised its holdings in shares of Mirum Pharmaceuticals by 59.2% in the 4th quarter. State Street Corp now owns 2,143,992 shares of the company’s stock worth $169,354,000 after purchasing an additional 797,088 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Mirum Pharmaceuticals by 10.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,420,375 shares of the company’s stock worth $112,196,000 after purchasing an additional 137,087 shares during the period. Finally, Wellington Management Group LLP raised its holdings in shares of Mirum Pharmaceuticals by 56.6% in the 4th quarter. Wellington Management Group LLP now owns 1,237,830 shares of the company’s stock worth $97,776,000 after purchasing an additional 447,141 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.